Compounds in this category
BPC-157 is the most-discussed compound in this category, and the one with the largest preclinical evidence base. The peptide is a 15-amino-acid synthetic sequence derived from a fragment of body protection compound, originally isolated from human gastric juice in the early 1990s. Predrag Sikiric's group at the University of Zagreb has published more than 100 rat studies since then. Multiple papers describe accelerated repair of transected Achilles tendon, medial collateral ligament, and rotator cuff injury models in rats. Reported effect sizes versus saline controls are large. Published mechanism proposals include modulation of the VEGFR2 pathway, accelerated angiogenesis at the injury site, and nitric oxide signaling.
No randomized controlled human trials on BPC-157 for tendon repair have been published. A 2024 review counted zero peer-reviewed Phase 2 or Phase 3 trials with tendon-specific endpoints. Case reports and small open-label series exist online and in conference abstracts. They are not equivalent to controlled trial data. BPC-157 is sold in the US and EU as a research chemical under Research Use Only (RUO) labeling. The compound is prohibited by the World Anti-Doping Agency under category S0 of the Prohibited List.
TB-500 is the second compound in this category by online discussion volume. It is a synthetic peptide marketed as equivalent to the active 17-amino-acid Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln fragment of thymosin beta-4, the actin-sequestering protein. Preclinical data in dermal wound healing, corneal repair, and tendon injury models exists. Pharmaceutical-grade thymosin beta-4 (under the development name RGN-259 and others) reached Phase 2 trials for dry eye and venous stasis ulcers. None of those programs targeted tendon repair specifically. The grey-market TB-500 sold as a research peptide is not the same regulated drug substance studied in clinical trials. WADA prohibition applies.
Pentadeca arginate is a newer entry, positioned as a stabilized BPC-157 analog. The peer-reviewed evidence is currently limited. Marketing claims for tendon and ligament repair outpace the published trial base. The compound page treats it as a hypothesis pending verification.
GHK-Cu (glycyl-L-histidyl-L-lysine-copper) has documented effects on collagen synthesis and extracellular matrix remodeling in cell models and human topical dermal trials. Tendon-specific human trial data is almost entirely absent. The compound is not WADA-prohibited at this time. Athletes should verify current status before use.
Mechanism proposals (and the limits of mechanistic plausibility)
Tendon repair peptides are proposed to act on angiogenesis at the injury site (BPC-157 via VEGFR2 and NO signaling), actin sequestration and cell migration (TB-500), or collagen synthesis and extracellular matrix remodeling (GHK-Cu). These mechanisms are partly characterized in vitro and in animal models.
Mechanistic plausibility is not clinical efficacy. Dozens of compounds with plausible mechanisms have worked in animals and failed in humans. The trial base required to confirm tendon-repair efficacy in humans involves controlled enrollment of patients with diagnosed tendinopathy or tendon rupture, MRI or ultrasound confirmation, structured rehab protocols, and follow-up of at least 12 months. None of the peptides in this category currently has that data.
What the realistic reader should understand
The most-published peptide in tendon-injury rat models (BPC-157) has zero published human RCTs for any tendon indication. The grey-market "TB-500" sold alongside it is not the same molecule that pharmaceutical companies have advanced through clinical pipelines. Pentadeca arginate is marketing-active and trial-thin. GHK-Cu has solid dermal evidence and no usable tendon trial.
Dosing is reported on each compound page as it appears in the cited literature, not as personal advice. PeptScope does not recommend, link, or rank vendors. Clinical confirmation of tendon-repair efficacy in humans remains the open question for this category.